Results 91 to 100 of about 676 (157)

Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA [PDF]

Chest, 2021
Paula K. Schweitzer, Geert Mayer, Russell Rosenberg, Atul Malhotra, Gary K. Zammit, Mark Gotfried, Patricia Chandler, Michelle Baladi, Kingman P. Strohl   +8 more
openaire   +1 more source

Wpływ objawów i leczenia narkolepsji na życie seksualne - aktualne dowody i doniesienia naukowe [PDF]

Introduction: Narcolepsy (NT) can manifest as excessive daytime sleepiness (EDS), cataplexy, hypnagogic (HHG) and hypnopompic (HHP) hallucinations, sleep paralysis, orgasmolepsy – all of which may affect patients\u27 functioning. The aim of the study was
Dyzma-Kasprzak, Agnieszka, Dyzma-Kasprzak, Agnieszka, Kasprzak, Karol, Kasprzak, Karol, Pukaluk-Lewinska, Agnieszka, Pukaluk-Lewinska, Agnieszka, Wingralek, Zuzanna, Wingralek, Zuzanna   +7 more
core   +2 more sources

A Review of Obstructive Sleep Apnea Treatment: The Role of Surgery in Therapy and Alternative Treatment Modalities [PDF]

Obstructive sleep apnea (OSA) is a common sleep disorder involving repeated upper airway obstructions during sleep, leading to hypoxia, fragmented sleep, and excessive daytime sleepiness. It is linked to significant cardiovascular and metabolic risks and
Borowski, Maciej, Dądela, Bartosz, Gnitecki, Szymon, Janczura, Szymon, Jasińska, Joanna, Kawalska, Eliza, Majewska, Emilia Maria, Markowski, Marcin, Zielonka, Kacper, Śliwa, Natalia   +9 more
core   +1 more source

A Case of Excessive Daytime Sleepiness [PDF]

, 2020
Chung, Augstine, De Cruz, Sharon
core  

Comparison of Solriamfetol and Modafinil on Arousal and Anxiety-Related Behaviors in Narcoleptic Mice. [PDF]

Neurotherapeutics, 2023
Sakai N, Nishino S.
europepmc   +1 more source

Efficacy and Safety of Solriamfetol on Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea in China: A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Randomized Clinical Trial. [PDF]

CNS Drugs
Cheng H, Deng L, Meng Z, Zhang W, Chen T, Chen R, Tang S, Lv Y, Su X, Liu Z, Zhang X, Wang X, Mao H, Zhang N, Yu H, Pan J, Xie Y, Tang J, Yin S, Wang Z, Tong M, Zhan S, Wang C, Wang B, Zhang W, Mi W, Lu L.   +26 more
europepmc   +1 more source

Psychomotor Vigilance Performance in Participants with Excessive Daytime Sleepiness in Obstructive Sleep Apnea or Narcolepsy Compared with SAFTE-FAST Model Predictions. [PDF]

Neurol Ther, 2023
Devine JK, Schwartz L, Hursh S, Asin J, de Vries N, Vonk PE, Vermeeren A, Donjacour CEHM, Vinckenbosch F, Ramaekers JG, Janssen H, Wang G, Chen D, Carter LP, Overeem S, Lammers GJ.   +15 more
europepmc   +1 more source

Advances in Non-CPAP Management of Obstructive Sleep Apnea: Spotlight on Pharmacological Therapies. [PDF]

J Pers Med
Siciliano M, de Scisciolo M, Fratini A, Sottani C, Giordani F, Brunetti V.   +5 more
europepmc   +1 more source

Pitolisant Improves Depressive Symptoms in CPAP-Treated Patients with Obstructive Sleep Apnea and Severe Residual Sleepiness: First 12-Month Clinical Experience. [PDF]

CNS Drugs
Caratozzolo D, Muscato G, Rizzo P, Gangemi C, Scionti A, Mancuso S, Vancheri C, Spicuzza L.   +7 more
europepmc   +1 more source

Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression. [PDF]

J Psychiatr Res, 2022
Krystal AD, Benca RM, Rosenberg R, Schweitzer PK, Malhotra A, Babson K, Lee L, Bujanover S, Strohl KP.   +8 more
europepmc   +1 more source